

October 28, 2026
Mochida Pharmaceutical Co., Ltd.

Announcement of Comprehensive Collaboration Agreement for Biosimilars

Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Naoyuki Mochida; hereinafter “Mochida”) hereby announces that it has entered into a comprehensive collaboration agreement with Qilu Pharmaceutical Co., Ltd. (Head Office: Jinan, Shandong Province, China; General Manager: ZHANG Hanchang; hereinafter “Qilu”) regarding the development and commercialization of Qilu's biosimilars in Japan.

Under this agreement, Mochida and Qilu will collaborate on the development and commercialization of multiple biosimilar candidates by Mochida in Japan.

In March 2026, Mochida and Qilu entered into a collaboration agreement concerning a biosimilar of follitropin alfa (genetical recombination) and are currently advancing development activities toward obtaining marketing authorization for the product in Japan. Through their collaboration on the biosimilar of follitropin alfa, the two companies have explored opportunities for further collaboration in the biosimilar field. As a result, Mochida and Qilu agreed to expand their collaboration beyond individual products to multiple biosimilars from a medium- to long-term perspective, leading to the conclusion of this agreement.

As a leading company in the biosimilar field in Japan, Mochida aims to enhance its biosimilar product portfolio and further strengthen its biosimilar business in Japan by expanding its collaboration with Qilu. Through these efforts, Mochida will provide patients with new treatment options.

About Qilu Pharmaceutical Co., Ltd.

Qilu Pharmaceutical (<https://en.qilu-pharma.com/>), established in 1958, is now one of the leading pharmaceutical companies in China, involved in the development, manufacturing, and distribution of pharmaceutical products. Qilu is China's No. 1 private pharmaceutical enterprise, achieving revenue of approximately USD 6 billion in 2025.

Qilu operates six R&D centers across China and the United States, supported by a strong pool of over 5,800 scientists. To date, Qilu has launched approximately 350 products and has established a robust pipeline comprising over 80 innovative products, more than 60 biosimilars, and over 200 generic products.

In addition, Qilu has a total bioreactor capacity of 240,000 liters, enabling commercial-scale production of biopharmaceuticals and biosimilars. Dedicated to offering high-quality & trustworthy medicines to the world and improving people's well-being, Qilu is vigorously expanding its global presence. Its finished dosage forms and active pharmaceutical ingredients have been approved by regulatory authorities in the United States, Europe, and other countries and regions. Qilu is currently exporting its products to over 100 countries and regions around the world.

Contact:

Mochida Pharmaceutical Co., Ltd.

Public Relations, Corporate Planning Department

Email: webmaster@mochida.co.jp

###

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
--